#USA #New York #Class Action #Securities Fraud #ADMA Biologics

ADMA Biologics Faces Legal Troubles Over Securities Fraud Claims

In recent news, ADMA Biologics, Inc. is embroiled in a securities fraud class action lawsuit after witnessing a dramatic drop in its stock price. The prominent law firm, Bleichmar Fonti & Auld LLP, has filed this lawsuit on behalf of investors who encountered significant losses. The lawsuit raises serious allegations of potential misconduct relating to the reported financial performance of the company.

Overview of the Situation

On March 24, 2026, ADMA Biologics's stock experienced a staggering decline of approximately 29%. This drop was triggered by allegations from Culper Research, which accused the company of channel stuffing – a practice that artificially inflates sales numbers by convincing distributors to purchase more product than they can sell. This revelation has rocked investor confidence and prompted the current legal actions.

Background of ADMA Biologics

ADMA Biologics is a biopharmaceutical company dedicated to producing specialty biologic products. Its key offering, ASCENIV, is a liquid immune globulin solution aimed at treating Primary Humoral Immunodeficiency in both adults and adolescents. The company has positioned itself at the forefront of manufacturing and marketing valuable biologics, achieving significant growth until recent claims surfaced.

Allegations Against ADMA Biologics

According to the allegations, ADMA's reported 20% growth in 2025 may have been overstated due to a deceptive channel stuffing scheme. This meant that, rather than reflecting genuine sales growth, the figures were artificially manipulated, leading to misleading reports to investors and stakeholders. Culper Research's investigation suggested that the company incentivized distributors to stock excessive amounts of ASCENIV through discounts and lenient payment terms, leading to inflated revenue figures and creating a misleading narrative of product demand.

The lawsuit alleges that if ADMA had not engaged in such practices, its actual revenue growth would have appeared as a decline of 3% rather than the reported growth. This significant discrepancy has not only affected the company’s stock valuation but has also put it under severe scrutiny from regulatory bodies and its investor base.

The Financial Impact

The ramifications of these allegations have been severe. Following the allegations, ADMA's stock saw a drop from $13.59 to $11.33 in a single day – a 16.6% reduction. In the days following the initial report, the stock continued to fall, further reflecting the unease permeating throughout the investor community. As prices continued to descend, investors found themselves faced with collective financial losses amounting to millions.

What Investors Should Know

The class action lawsuit has been organized in the U.S. District Court for the District of New Jersey, specifically labeled as _Mazzarino v. ADMA Biologics, Inc., et al._ Potential class members have until August 10, 2026, to file for lead plaintiff status in the litigation. While the lawsuit asserts violations of the Securities Exchange Act of 1934 concerning Sections 10(b) and 20(a), it aims to hold the company, along with its senior executives, accountable for the losses incurred by shareholders due to alleged securities fraud.

What Are Your Options?

If you have invested in ADMA Biologics and suffered losses, it’s crucial to stay informed about your legal rights. Bleichmar Fonti & Auld LLP is offering a contingency-based representation, meaning that investors are not required to pay any legal fees upfront. Instead, any potential costs will be submitted for court approval.

For those seeking to understand their legal standing and possibly join the class action, additional information can be found through the law firm's dedicated case page. Potential claimants are encouraged to act promptly and gather the necessary documentation in anticipation of the upcoming deadlines.

Conclusion

The ongoing legal troubles of ADMA Biologics serve as a reminder to investors about the importance of due diligence and the potential risks involved in stock market investments. With legal proceedings underway, this case signifies a significant moment not only for ADMA but also for investors keeping a close watch on ethical practices within the biopharmaceutical sector.

For further information on how to engage in the class action or understand the nuances of the lawsuit, visit BFA Law's case page.